811 reports of this reaction
1.2% of all MINOXIDIL reports
#17 most reported adverse reaction
APPLICATION SITE DRYNESS is the #17 most commonly reported adverse reaction for MINOXIDIL, manufactured by Kenvue Brands LLC. There are 811 FDA adverse event reports linking MINOXIDIL to APPLICATION SITE DRYNESS. This represents approximately 1.2% of all 65,386 adverse event reports for this drug.
MINOXIDIL has an overall safety score of 78 out of 100. Patients taking MINOXIDIL who experience application site dryness should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE DRYNESS is a less commonly reported adverse event for MINOXIDIL, but still significant enough to appear in the safety profile.
In addition to application site dryness, the following adverse reactions have been reported for MINOXIDIL:
The following drugs have also been linked to application site dryness in FDA adverse event reports:
APPLICATION SITE DRYNESS has been reported as an adverse event in 811 FDA reports for MINOXIDIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE DRYNESS accounts for approximately 1.2% of all adverse event reports for MINOXIDIL, making it a notable side effect.
If you experience application site dryness while taking MINOXIDIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.